Clinical trials: Rectum Neoplasm
Rectal Cancer
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Standard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity.
- Trial name
- ETAP (NCT02584985)
- Testing
- ETAP, Standard Transabdominal Laparoscopic Proctectomy
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Institut Paoli-Calmettes
Rectum Cancer, Faecal Incontinence
Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer.
The occurrence of colorectal cancer has increased from the third most common cancer in 2018 to the second most common cancer in 2023.
- Conditions
- Rectum Cancer, Faecal Incontinence, Faecal Incontinence with Faecal Urgency, Low Anterior Resection Syndrome
- Trial name
- NCT06601985
- Testing
- J-pouch anastomosis, direct anastomosis
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Shanghai 10th People's Hospital
Rectal Cancer
Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)
The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.
- Trial name
- NCT06380855
- Testing
- Flexible colonoscope assisted hybrid transanal total mesorectal resection
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Colo-rectal Cancer
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance.
- Conditions
- Colorectal Cancer, Colo-rectal Cancer, ctDNA, Gastro-Intestinal Disorder
- Trial name
- NCT04084249
- Testing
- ctDNA-analysis, Intensified Follow-up Schedule
- Where
- 10 sites in Denmark
- Volunteers
- 359 people
- Sponsor
- Claus Lindbjerg Andersen
Colorectal Cancer
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00006015
- Testing
- trastuzumab, fluorouracil, leucovorin calcium
- Where
- 47 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Ulcerative Colitis, Rectal Cancer
Surgical and Oncological Outcomes in Patients With Ulcerative Colitis-associated Rectal Cancer
This is a retrospective observational study to investigate the short-term surgical outcomes, and long-term oncological outcomes of patients diagnosed with Ulcerative colitis and rectal cancer.
- Trial name
- UC-RectalK (NCT04659148)
- Testing
- Total proctocolectomy
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Istituto Clinico Humanitas
Breast Neoplasms, Colonic Neoplasms
Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
The purpose of this study is to determine whether anesthesia maintained with propofol results in better one- and five-year-survival than anesthesia maintained with sevoflurane.
- Conditions
- Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- CAN (NCT01975064)
- Testing
- Propofol, Sevoflurane
- Where
- 15 sites in China, Poland and 1 more
- Volunteers
- 5,774 people
- Sponsor
- Uppsala University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
- Trial name
- AMPLIFY-7P (NCT05726864)
- Testing
- ELI-002 7P
- Where
- 28 sites in United States
- Volunteers
- 158 people
- Sponsor
- Elicio Therapeutics
Rectal Cancer, Adaptive Radiotherapy
the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer
Based on preliminary findings on the motion error of the clinical target volume (CTV) in MR-guided adaptive radiotherapy (MRgART) for locally advanced rectal cancer (LARC), this study aims to reduce CTV-to-PTV margins and…
- Trial name
- NCT07080411
- Testing
- short course radiotherapy using MR-linac
- Volunteers
- 49 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectum Cancer, Recurrent, Brachytherapy, Radioisotope
The Physical Dosimetry Study and Preliminary Clinical Results of 3D-printing Non Co-planar Template Assisted With CT-guidance for Iodine-125 Seed Brachytherapy in Pelvic Recurrent Rectum Carcinoma After Surgery and External Beam Radiotherapy
This study observes the efficacy and side effects of 3D-printing non co-planar template(3D-PNCT) assisted with CT-guidance for radioactive Iodine-125 seed(RIS) brachytherapy in pelvic recurrent rectum carcinoma retrospectively…
- Trial name
- NCT03890926
- Testing
- radioactive Iodine-125 seed implantation under the guidance of 3D template
- Volunteers
- 66 people
- Sponsor
- Peking University Third Hospital
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lower Abdominal Surgery, Pelvic Surgery
Objective to Evaluate the Safety and Effectiveness of LED Light Source System for Endoscopy in Ureteral Radiography
This clinical trial is a prospective, multi-center, single-blind, parallel, randomized controlled superiority clinical trial. The trial will be carried out in 5 centers, involving 120 subjects as estimated who will be divided…
- Trial name
- IRIS (NCT04561414)
- Testing
- LED light source system for endoscope, Ureteral stent (Cook Ireland Ltd.)
- Where
- 4 sites in China
- Sponsor
- Stryker Orthopaedics
Colorectal Cancer, Colonic Neoplasms
Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer
This study is designed to evaluate the short-term and long-term results after single incision laparoscopic surgery for colorectal cancer（SILSC） compared with conventional laparoscopic surgery for colorectal cancer（CLSC）.
- Conditions
- Colorectal Cancer, Colonic Neoplasms, Rectal Neoplasms, Colon Disease
- Trial name
- mSILSC (NCT03633539)
- Testing
- Single-incision Laparoscopic Surgery, Conventional Laparoscopic Surgery
- Where
- China
- Sponsor
- Ruijin Hospital
Human Papilloma Virus Infection
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
This trail is to evaluate the safety profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy Chinese women ages 20-45 and determine the optimal ratio of…
- Trial name
- NCT05694728
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
- Where
- China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Rectal Cancer
RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study
Aim: We evaluated the surgical outcomes of 3 groups of patients with rectal cancers - RAPIDO vs standard long course radiotherapy (LCRT) vs upfront surgery to objectively determine the effects of TNT on TME.
- Trial name
- RAPIDO (NCT06212128)
- Testing
- RAPIDO TNT, LCRT
- Volunteers
- 57 people
- Sponsor
- Sengkang General Hospital
Rectal Cancer
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Currently the 3-year disease free survival of patients with locally advanced rectal cancer is about 50%. Current standard treatment for patients at high risk of failing locally and/or systemically includes pre-operative long…
- Trial name
- RAPIDO (NCT01558921)
- Testing
- M1 scheme, standard long course chemoradiotherapy
- Where
- 56 sites in United States, Denmark and 5 more
- Volunteers
- 920 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006115
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 16 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Rectal Neoplasms
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Primary objective: Pathological complete response (ypT0N0) rate Secondary objectives: Histopathological R0 resection rate Pathological downstaging (ypT0-T2N0) rate One month surgical complication rate Predictive value of…
- Trial name
- NCT00174616
- Testing
- Oxaliplatin, capecitabine, radiotherapy
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Rectal Cancer
Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients
The ACO/ARO/AIO-21 investigator-driven, open-labeled, phase I drug re-purposing trial will assess whether the IL-1 receptor antagonist Anakinra can be safely combined with fluoropyrimidine-based chemoradiotherapy (CRT) in…
- Trial name
- ACO/ARO/AIO-21 (NCT04942626)
- Testing
- Kineret 100 MG in 0.67 ML Prefilled Syringe, Capecitabine, Radiotherapy
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Goethe University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.